

Date: 5th August, 2023

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Unaudited Financial Results

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Unaudited Financial Results for the quarter ended 30th June, 2023, published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 5th August, 2023

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited



Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of Statement of Consolidated Unaudited Financial Results for
the quarter ended 30th June, 2023**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,486.15	1,262.14	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	120.60	(65.88)	341.99
Total Comprehensive Income for the period	119.66	(60.58)	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	6.14	(3.35)	17.40
Research and Development Expenses	118.59	261.05	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,332.27	1,177.25	5,149.00
Profit Before Tax	97.53	(49.39)	345.93
Profit After Tax	97.53	(49.39)	346.73
Research and Development Expenses	117.75	252.82	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin
Chairman and CEO

Place: Vadodara

Date: 4th August, 2023

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,486.15	1,262.14	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	120.60	(65.88)	341.99
Total Comprehensive Income for the period	119.66	(60.58)	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	6.14	(3.35)	17.40
Research and Development Expenses	118.59	261.05	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,332.27	1,177.25	5,149.00
Profit Before Tax	97.53	(49.39)	345.93
Profit After Tax	97.53	(49.39)	346.73
Research and Development Expenses	117.75	252.82	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Place: Vadodara

Date: 4th August, 2023Chirayu Amin
Chairman and CEO



ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123
 Regd. Office: Alembic Road, Vadodara - 390 003
 Tel: 0265-6637300
 Email: apl.investors@alembic.co.in
 Website: www.alembicpharmaceuticals.com

Extract of Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2023

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Total Income from Operations	1,486.15	1,262.14	5,652.62
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	129.76	(67.38)	354.59
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	120.60	(65.88)	341.99
Total Comprehensive Income for the period	119.66	(60.58)	355.36
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	6.14	(3.35)	17.40
Research and Development Expenses	118.59	261.05	721.84

Notes:

1. Standalone details	Quarter Ended		Year Ended
	30.06.2023	30.06.2022	31.03.2023
	Unaudited	Unaudited	Audited
Income from Operations	1,332.27	1,177.25	5,149.00
Profit Before Tax	97.53	(49.39)	345.93
Profit After Tax	97.53	(49.39)	346.73
Research and Development Expenses	117.75	252.82	699.39

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at www.alembicpharmaceuticals.com and the Stock Exchange's website at www.nseindia.com and www.bseindia.com

For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin
 Chairman and CEO

Place: Vadodara

Date: 4th August, 2023